okyopharma.com - צמיחת הכנסות ב-12 חודשים נגררים OKYO

Stable demand for dry eye therapy guarantees OKYO Pharma Limited (OKYO) long-term rent. The sales dynamics over the last 12 months year-over-year confirm this trend, where 0.00 is recorded as the baseline value. R&D efforts in the US and UK strengthen the company's position, while patent protection and stringent FDA requirements create significant barriers to entry for new market players.
OKYO Pharma Limited (OKYO) - פילוחי מדדים ודוחות פיננסיים

For OKYO Pharma Limited (OKYO), which focuses on dry eye medications, the year-over-year (12-month) relative revenue growth rate serves as an indicator of commercial viability. This metric captures the percentage change in sales volume over a rolling year compared to the same period of the previous cycle. The calculation is based on market consensus, bypassing official reporting delays. For a single-product business, this price action reflects the success of the drug's implementation, while steady growth confirms scaling within the mass market.